VENLO, Netherlands and KOLKATA, India, April 21 /PRNewswire-Asia/ -- QIAGEN and the Chittaranjan National Cancer Institute (CNCI) today announced a collaboration to establish the first large-scale cervical cancer screening program for women in Kolkata, India. QIAGEN (Nasdaq: QGEN; Frankfurt Prime Standard: QIA) will provide its diagnostic tests for the human papillomavirus (HPV) -- the primary cause of cervical cancer. CNCI will conduct the screening and provide appropriate treatment as needed.
The "QIAGENcares Kolkata Project" will use QIAGEN's hybrid capture 2 (hc2) HPV DNA testing technology (also known as the digene(R) HPV Test) to screen women for cancer-causing types of HPV to identify those with or at risk for developing cervical cancer. Participating women will also be screened using VIA (visual inspection with acetic acid) as per the Indian National Guidelines for Cervical Screening. Screening will take place at community-based mobile field clinics in the villages neighboring Kolkata. Women found to have cervical cancer or pre-cancer will be immediately treated at the field clinic -- a process referred to as "screen and treat" -- or referred to the CNCI for follow up. The project also includes educational campaigns to raise awareness about HPV, cervical cancer, and other women's health issues. The initiative will be conducted over 5 years and is expected to reach 50,000 women.
Despite being a preventable cancer with a known primary cause, cervical
cancer claims nearly 300,000 lives every year -- with 80% of these deaths
occurring in developing countries. India has more cervical cancer cases than
any other country in the world. The World Health Organization (WHO) estimates
that every year more than 130,000 Indian women are diagnosed with cervical
cancer and more than 74,000 die from it. This makes ce
|SOURCE QIAGEN; Chittaranjan National Cancer Institute|
Copyright©2009 PR Newswire.
All rights reserved